Led · Equity · Sep 2020

Neo Medical combines advances in biomechanics with an intraoperative AI-driven augmented reality data platform (ADVISE) and proprietary force-control technologies to support thoracolumbar fusion procedures. Its Neo Universal portfolio is designed to treat any operable thoracolumbar condition in a single procedural platform and supports both MIS and open approaches. The company couples its technologies with a 'SmartService' distribution model to optimize perioperative processes and improve operational efficiency. Since commercial launch in 2016, Neo’s technologies have been used to treat around 36,000 patients, with studies showing implant-failure rates reduced by up to three-fold, infection risk cut by half, surgery time reduced by up to 29%, and revisionary surgery needs lowered by as much as 50%. Neo has a strong European presence and operating subsidiaries in the U.S., Spain, France, and Germany and is rapidly expanding in the U.S. and other markets. The company plans to deploy new complementary products, enhance ADVISE capabilities, and increase market share—with an immediate focus on expanding its U.S. business and outpatient center opportunities. Neo Medical, based in Lausanne, Switzerland, develops controlled-fixation solutions designed to enable a more Functional Fusion in spinal surgery. Its ADVISE™ augmented reality platform complements an existing optimized implants and instruments platform, creating a technology ecosystem of universal implants, smart instruments, and software. The company says this complete system supports enhanced outcomes across preoperative planning, intraoperative actions, and postoperative recovery. Neo Medical is led by CEO Vincent Lefauconnier. The company raised $20.6M in funding and intends to use the proceeds to accelerate commercial deployment of ADVISE™—with a particular focus on the U.S.—and to expand product development and its team. Neo Medical, based in canton Vaud, Switzerland, develops a new generation of spinal surgery products using only five multi-functional instruments to cover most spine indications. Its proprietary designs aim to ensure anatomically neutral, balanced, and stable spine load-bearing to achieve a Functional Fusion. The company emphasizes a value-based care approach that it says preserves environmental sustainability across the healthcare system. Neo Medical is deploying single-use, sterile-packed procedure instrumentation intended for acute care hospitals, outpatient hospitals, and ambulatory surgery centres. Planned work with its partner includes development of a cervical platform and broader deployment of sterile-packed instruments for cervical spine procedures. The solutions aim to increase operating-room efficiency, reduce procedural times and costs, improve patient outcomes, and lower infection rates. Neo Medical develops a surgical platform for spinal surgery that currently comprises five instruments and fourteen implants intended to cover most spine indications. Its Controlled-Fixation technology is designed to enable a post-operative anatomically neutral, balanced, and stable spine, aiming to reduce screw loosening, hardware failure, and re-operation risks while improving patient outcomes. The company has CE and FDA approvals for its pedicle screw system (Sept 2016 and Sept 2017) and for its cages (Dec 2019 and Jan 2020). Since its market launch in Q2 2017, Neo Medical products are used in 250 hospitals worldwide. The company focuses commercial efforts on five strategic markets: the USA, Germany, Spain, Switzerland, and France. Neo Medical says it will use the financing to finance global growth and expansion in targeted key markets.